Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas.
Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →
| Cuenta de resultados | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Ingresos totales | JPY 825.4B | JPY 789.4B | JPY 741.8B | JPY 744.4B |
| Beneficio bruto | JPY 634.2B | JPY 620.6B | JPY 586.4B | JPY 566.6B |
| Ingresos operativos (EBIT) | JPY 44.1B | JPY 54.4B | JPY 53.4B | JPY 40.0B |
| Ingresos netos | JPY 38.6B | JPY 46.4B | JPY 42.4B | JPY 55.4B |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de 4523. /companies/us/4523
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms